Our team compared the TIM3 expression levels of HSCs in MDS patients, AML patients, and healthy volunteers, and found that the TIM3 expression levels of HSCs in high-risk MDS and AML patients were abnormally high, and TIM3+ HSCs exhibited aberrant differentiation, hyperproliferation, and reduced apoptosis (24). This evidence concerns the gene HAVCR2 and myelodysplastic syndrome.